Imatinib Normon (Imatinib)

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways and is used in several hematologic and solid‑tumor indications.

• Chronic myeloid leukemia (CML): provides disease control by inhibiting BCR‑ABL‑driven proliferation.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): facilitates remission through blockade of the same fusion kinase.
• Gastrointestinal stromal tumor (GIST): suppresses tumor growth by targeting c‑KIT and PDGFR signaling.

• Imatinib selectively binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, stabilising them in an inactive conformation. This prevents phosphorylation of downstream substrates, halting signal transduction that drives cell proliferation and survival, ultimately leading to apoptosis of malignant cells that depend on these kinases.

Adverse reactions vary in frequency and severity. Patients should be monitored regularly for both common and serious events.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the lower limbs.
• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects

• Neutropenia: marked reduction in white blood cells, increasing infection risk.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: signs of reduced cardiac function, such as dyspnea or edema.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary hypertension: elevated pressure in lung arteries causing shortness of breath.

Before initiating therapy, clinicians should evaluate baseline health status and monitor for emerging issues.

• Blood count monitoring: perform complete blood counts regularly to detect cytopenias.
• Liver function assessment: check hepatic enzymes before and during treatment.
• Cardiac evaluation: assess baseline cardiac function and watch for signs of heart failure.
• Pregnancy considerations: avoid use unless benefits outweigh potential fetal risks.
• Storage: Store at room temperature: keep in the original container, protect from moisture and light.

Imatinib may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise imatinib plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug concentrations.
• Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: may increase anticoagulant effect, requiring INR monitoring.
• Digoxin: potential for increased serum digoxin levels.
• Other CYP3A4 substrates (e.g., midazolam, statins): may need dose adjustments based on clinical response.